Xilio Therapeutics, Inc.
XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2ā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.11
Price+0.29%
$0.03
1Y
Price
Market Cap
$59.900m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-83.6%
EBITDA Margin-85.4%
Net Profit Margin-91.8%
Free Cash Flow Margin-83.6%
EBITDA Margin-85.4%
Net Profit Margin-91.8%
Free Cash Flow MarginRevenue
$53.484m
+401.3%
1y CAGR+133.8%
3y CAGR+100.3%
5y CAGREarnings
-$31.300m
-0.4%
1y CAGR+12.3%
3y CAGR+5.1%
5y CAGREPS
-$5.65
+40.4%
1y CAGR+38.0%
3y CAGR+24.2%
5y CAGRBook Value
$72.545m
$163.487m
Assets$90.942m
Liabilities$6.638m
DebtDebt to Assets
4.1%
-0.1x
Debt to EBITDAFree Cash Flow
-$57.365m
+4.5%
1y CAGR+29.6%
3y CAGR+23.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company